Resilient Resubmits MDMA-Assisted Therapy NDA for PTSD After FDA Rejection — Multidisciplinary Association for Psychedelic Studies (MAPS)

Event summary

Resilient Pharmaceuticals resubmitted its NDA for MDMA-assisted therapy for PTSD to the FDA on August 9, 2026.
The resubmission follows a Complete Response Letter issued by the FDA in August 2024, which requested additional research on durability of response, safety characterization, and bias minimization.
MAPS, which initiated and funded the clinical research on MDMA-assisted therapy, has no active role in Resilient’s drug development program.
The FDA published final guidance on psychedelic drugs in July 2026, reflecting approaches developed by MAPS over decades of collaboration with the agency.

The big picture

Resilient Pharmaceuticals' resubmission of its NDA for MDMA-assisted therapy marks a critical step in the regulatory pathway for psychedelic-assisted therapies. The FDA's updated guidance reflects decades of collaboration with MAPS, highlighting the evolving landscape for evaluating drugs delivered as part of therapy. This development underscores the strategic importance of rigorous scientific evaluation and the potential market impact of approved psychedelic treatments for mental health conditions.

What we're watching

Regulatory Dynamics: How the FDA's final guidance on psychedelic drugs will influence the evaluation of Resilient's resubmitted NDA.
Therapeutic Model: Whether the therapeutic model, including trained therapist teams and rigorous safety protocols, can effectively serve patients pending FDA approval.
Accessibility: The pace at which treatments for trauma-affected individuals will become accessible if the NDA is approved.